ATLANTA — Novo Nordisk’s Wegovy enhanced symptoms and physical perform in sufferers who had weight problems, diabetic issues, and a widespread type of coronary heart failure, boosting Novo’s attempt to get the well-known drug accredited for yet an additional utilization outside of fat loss.
The analyze, staying offered listed here on Saturday at the American School of Cardiology meeting and revealed in the New England Journal of Medicine, experiences benefits from the second massive demo Novo has executed on Wegovy in coronary heart failure with preserved ejection portion, or HFpEF. The first trial, which showed good success past calendar year, was in individuals who had obesity and HFpEF, but not diabetes.
Novo stated it submitted the success of these two trials to regulators previously this 12 months and is looking for approval for a new sign in HFpEF. Wegovy just past thirty day period got Food and drug administration clearance for its first utilization in addition to fat reduction — protecting against cardiovascular issues in folks with coronary heart sickness.
Continue to STAT+ to study the entire story…